91 results about "Lipid accumulation" patented technology

This invention relates to the application of oridonin in the preparation of agents that improve muscle function, specifically by improving skeletal muscle dysfunction, enhancing insulin sensitivity, promoting myoblast differentiation into myotube cells, and / or increasing myoblast insulin sensitivity. Using an in vitro C2C12 myoblast model, this invention demonstrates that oridonin can promote myoblast differentiation and growth and increase C2C12 myoblast insulin sensitivity. Through an obesity-induced skeletal muscle dysfunction model, it is demonstrated that oridonin can improve skeletal muscle dysfunction and insulin resistance by increasing muscle strength, muscle endurance, muscle mass, and reducing muscle lipid accumulation. This invention provides new insights for drug research on improving skeletal muscle dysfunction and enhancing insulin sensitivity, and also enriches the pharmacological system of oridonin.

The invention discloses application of rutin hydrate in preventing and treating repeated embryo planting failure, and belongs to the technical field of assisted reproduction. It is found for the first time that CD36 is a key membrane protein for lipid transport and uptake of EECs, rutin hydrate competitively inhibits combination of CD36 and natural ligands of CD36, abnormal lipid excessive uptake is remarkably blocked, lipid accumulation and lipid toxicity damage in cells are effectively relieved, and the effect of inhibiting EECs lipid transport and uptake is achieved. And finally, the endometrial receptivity defect related to RIF is reversed, and the embryo adhesion and implantation capability is remarkably improved. Therefore, rutin hydrate provides a brand new strategy for developing targeted therapy drugs for RIF, especially for lipid metabolism disorder type endometrial receptivity badness, and has remarkable clinical application and transformation prospects.

The present invention relates to an anti-obesity composition comprising a Geranium wilfordii extract. The extract according to the present invention exhibits an excellent body fat reduction effect by inhibiting lipid accumulation, and thus can be used in pharmaceutical and food fields as an anti-obesity composition.

The present invention aims to provide a novel pharmaceutical composition that can be used for the treatment or prevention of lysosomal storage diseases, particularly Niemann-Pick disease. [Solution] The present invention provides a pharmaceutical composition for the treatment or prevention of lysosomal storage diseases, characterized by containing a modified γ-cyclodextrin as an active ingredient, wherein the modified γ-cyclodextrin has a monovalent group derived from galacturonic acid that is bonded to a sugar residue of the γ-cyclodextrin via an amide bond.

The invention provides application of a xanthine derivative in preparation of a medicine for preventing and / or treating fatty liver diseases related to metabolic dysfunction, and belongs to the technical field of medicine preparation. The invention relates to an application of a xanthine derivative 8-[(2, 3-dihydroxy propyl) sulfo]-3-methyl-7-[(4-methylphenyl) methyl]-1H-purine-2, 6-diketone in preparation of a medicine for preventing and / or treating fatty liver diseases related to metabolic dysfunction. The xanthine derivative has dual efficacy of improving liver cell insulin sensitivity and / or reducing liver cell lipid accumulation, and provides a new way for treatment of metabolic dysfunction related fatty liver diseases and preparation of related clinical drugs.

This invention discloses the application of American ginseng glycoprotein extract in the preparation of drugs for treating alcoholic liver disease, belonging to the field of biomedical technology. This invention verifies that TD can significantly reduce serum ALT, AST, and TG levels in ALD mice, effectively reducing liver damage and lipid accumulation; inhibit NLRP3 protein expression and its downstream targets, effectively alleviating liver inflammation and pyroptosis; and improve intestinal flora imbalance in ALD mice. American ginseng glycoprotein extract has multi-target protective effects against alcoholic liver disease, reducing alcohol-induced liver tissue inflammation and oxidative stress damage. It has a mild composition and high safety profile, and can synergistically exert effects in liver protection, anti-inflammation, and antioxidation, making it suitable for adjunctive intervention and long-term management of alcoholic liver disease, providing a natural, mild, and effective protective pathway for alcoholic liver damage.

This invention discloses a polypeptide with anti-wrinkle and oil-controlling effects, belonging to the field of cosmetic polypeptide technology. The polypeptide is heptapeptide-6, with the amino acid sequence Asn-Asp-Glu-Gly-Leu-Tyr-Leu. At concentrations of 0.001 mg / mL to 0.1 mg / mL, heptapeptide-6 significantly promotes the synthesis of type I collagen and elastin by human skin fibroblasts, exhibiting excellent anti-wrinkle and firming activity. At concentrations of 1 ppm to 50 ppm, it significantly inhibits lipid accumulation in *C. elegans* and lipid expression in zebrafish, with a maximum lipid inhibition rate of 24.38%, and also demonstrates clear oil-controlling activity. This invention's polypeptide has a single structure, overcoming the shortcomings of existing skincare polypeptides with single efficacy and complex formulations. It features stable processing, high safety, and is suitable as a core active ingredient in anti-wrinkle and oil-controlling cosmetics, providing a new avenue for the development and application of multifunctional skincare polypeptides.

The invention discloses a novel medical application of Chiglitazar, Indeglitazar and LZ03, and belongs to the technical field of medicines. The invention relates to a novel medical application of Chiglitazar, Indeglitazar and LZ03. The new application of the medicine specifically refers to application of a PPAR universal agonist Chiglitazar, Indeglitazar, LZ03 or pharmaceutically acceptable salts thereof to preparation of a medicine for preventing and / or treating Duchenne muscular dystrophy, Duchenne muscular dystrophy skeletal muscle lipid ectopic deposition and Duchenne muscular dystrophy skeletal muscle aplastic disorder. The invention further relates to a preparation method of the medicine for preventing and / or treating the Duchenne muscular dystrophy skeletal muscle aplastic disorder and the application of the PPAR universal agonist Chiglitazar, Indeglitazar, LZ03 and the pharmaceutically acceptable salts thereof. It is proved for the first time that the three compounds can effectively improve core pathological injuries of Duchenne muscular dystrophy, relieve muscle fiber necrosis, skeletal muscle lipid accumulation and aplastic disorder, remarkably improve the skeletal muscle function, fill the application blank of the compounds in the field of Duchenne muscular dystrophy treatment, and have broad application prospects in treatment of Duchenne muscular dystrophy. A brand new candidate drug and a treatment thought are provided for prevention and / or treatment of Duchenne muscular dystrophy, and important clinical application value is achieved.

The invention discloses a pharmaceutical composition for improving glucose and lipid metabolism disorder by combining N-p-coumaroyl octoamine and rotundine and application of the pharmaceutical composition, and belongs to the field of biological medicine and metabolic disease treatment. In a db / db diabetic mouse model, it is found that NTPC (10 mg / kg) or ROT (10 mg / kg) single drugs can improve hyperglycemia and insulin resistance and reduce blood fat, and low-dosage combination (5 mg / kg of NTPC and 5 mg / kg of ROT) shows the most significant metabolism improvement effect which is obviously better than that of a single drug group. In an in-vitro fatty acid stimulation model, lipid accumulation in cells can be more remarkably reduced through combination of the two drugs, and fatty acid synthesis genes are inhibited.

The present application discloses a plant lactobacillus CCFM1366 capable of transforming various pueraria flavones and having the effects of alcoholism relieving and liver protecting, and a postbiotic prepared from the plant lactobacillus CCFM1366, and belongs to the technical field of microorganisms. The plant lactobacillus CCFM1366 and the postbiotic prepared from the plant lactobacillus CCFM1366 have at least one of the following effects: (1) improving alcohol metabolism enzyme activity and enhancing alcohol metabolism; (2) improving liver steatosis, lipid accumulation, oxidative stress and inflammatory response caused by long-term alcohol exposure; (3) reducing ROS synthesis and thereby reducing oxidative damage to liver cells, promoting the synthesis of antioxidants and thereby improving the protective effect on liver cells; and (4) reducing inflammatory response. The plant lactobacillus CCFM1366 and the postbiotic prepared from the plant lactobacillus CCFM1366 can be used for preparing functional food and / or dietary supplements with the potential of alcoholism relieving and liver protecting, and have great application prospect.

The invention discloses a mesenchymal stem cell preparation and application thereof, and belongs to the technical field of cell biology. The mesenchymal stem cell preparation is a mesenchymal stem cell pretreated by a combined drug of ziyuglycoside II and shikonin. Through drug pretreatment, the antioxidant capacity of the mesenchymal stem cells is synergistically enhanced, the survival rate of the cells after transplantation is enhanced, the treatment effect of the cells on the NAFLD hepatocytes is remarkably enhanced, and lipid accumulation in the hepatocytes is effectively reduced. Therefore, the invention provides a novel method for enhancing the treatment capacity of the mesenchymal stem cells NAFLD, the method is suitable for bone marrow and umbilical cord mesenchymal stem cells, and an efficient and reliable preparation and an optimization scheme are provided for clinical stem cell treatment of the NAFLD.

The invention belongs to the technical field of medicines, and particularly relates to application of urolithin A and beta-nicotinamide mononucleotide in preparation of a medicine for treating diabetes. The invention finds that when the urolithin A and the beta-nicotinamide mononucleotide are independently used, the hypoglycemic effect on diabetic mice cannot be realized, and when the urolithin A and the beta-nicotinamide mononucleotide are jointly used, the symptoms of diabetes and insulin resistance caused by high fat diet can be remarkably improved; the glucose tolerance and the insulin tolerance are improved; meanwhile, the content of low-density lipoprotein and cholesterol in a mouse body is reduced, so that the risk of thrombus occurrence is reduced; in addition, combined medication can significantly reduce liver cell lipid accumulation and improve mitochondrial morphological abnormality. The invention provides a brand new technical scheme and experimental basis for treating diabetes caused by high fat diet and relieving insulin resistance, and has important medical application value.

The invention relates to application of cepharanthine in preparation of medicines for preventing or treating metabolic dysfunction related fatty liver diseases (Metabolic-associated fatty liver diseases), and particularly relates to application of cepharanthine in preparation of medicines for preventing or treating metabolic dysfunction related fatty liver diseases (Metabolic-associated fatty liver diseases). The invention relates to an application of MASLD in a medicine, and belongs to the technical field of biological medicines. In an in-vivo experiment, a mouse MASLD model is established by adopting methionine choline deficiency diet induction, and the treatment effect of cepharanthine on MASLD is researched. Experimental results show that the cepharanthine can significantly reduce the levels of triglyceride, glutamic-pyruvic transaminase, glutamic oxalacetic transaminase and other indexes of MASLD mice; a pathological detection result shows that cepharanthine can effectively reduce liver lipid deposition and inflammatory infiltration. In-vitro experiments prove that cepharanthine can effectively reduce the content of free fatty acid (Free Fatty Acid); fFA (Fatty Acid) induced HepG2 (HepG2) cell lipid accumulation and lipopolysaccharides (lipopolysaccharides) induced HepG2 cell lipid accumulation and lipopolysaccharides (FFA) induced HepG2 cell lipid accumulation; the THP-1 cell inflammatory response is induced by LPS (Lipopolysaccharide). In conclusion, the cepharanthine shows remarkable anti-lipid accumulation and anti-inflammatory effects in in-vivo and in-vitro experiments, can be used for preparing the medicine for preventing or treating MASLD, and has a wide application prospect.

The invention relates to an application of oligosporine in preparation of a weight-reducing medicine. The invention finds that the oligosporine B can reduce the weight of mammals. Moreover, the further research finds that the weight loss of mammals can be realized due to the fact that triglyceride in fat cells is hydrolyzed into free fatty acid and glycerol by mainly enhancing the activity of a key rate-limiting enzyme responsible for lipid metabolism in the fat cells so as to reduce the blood fat level and lipid accumulation in the fat cells, so that the weight loss of the mammals can be realized. Therefore, the weight loss is realized by reducing the adipose tissue mass.

The present invention provides a basis for using soluble fiber, particularly compositions comprising Agave fructans, to prevent or treat the accumulation of lipids, particularly ceramides in the liver and brain and lipofuscin in the liver, improving the overall integrity of both organs, with treatment being feasible to prevent fatty liver disease and also prevent Alzheimer's disease (AD). In the present invention, we analyze alterations in lipid metabolism in the liver and ceramide production in the brain of transgenic mice (APP / PS1, TG) for AD. Our results indicate that microvesicular lipid accumulation within hepatocytes is increased in TG mice compared to the control group. Furthermore, in the brains of TG mice, a greater accumulation of ceramides is observed in the somatosensory cortex and entorhinal cortex; in the CA1 region of the hippocampus and in the motor cortex, no significant increase was observed when compared to the control group.

This invention discloses a fish-derived bioactive peptide with dual functions of enhancing saltiness and inhibiting adipocyte differentiation, and its applications, belonging to the field of biotechnology. The bioactive peptide is a γ-glutamylarginine peptide with the general formula γ-[Glu]n-Arg, where n is an integer from 1 to 4. This invention efficiently prepared a series of γ-[Glu]n-Arg peptides through a targeted enzymatic synthesis method, further elucidating the dual effects of this bioactive peptide at the molecular mechanism level. The bioactive peptide can effectively enhance saltiness perception by binding to the saltiness receptor TMC4, and inhibit adipocyte differentiation and reduce lipid accumulation through multiple targets by downregulating PPAR-γ, C / EBPα, and FAS genes, and upregulating AMPK and HSL genes. This invention provides a reliable scientific basis and technical support for developing innovative food ingredients with both flavoring and health functions.

The invention belongs to the technical field of comprehensive utilization of oyster mushrooms, and provides an oyster mushroom active peptide for inhibiting foaming of macrophages and a preparation method of the oyster mushroom active peptide. The method comprises the following steps: taking oyster mushroom as a raw material, preparing oyster mushroom protein through alkali extraction and acid precipitation, preparing a crude product of the oyster mushroom active peptide for inhibiting foaming of macrophages through compound enzymatic hydrolysis of the oyster mushroom protein by pepsin, trypsin and chymotrypsin, and separating and purifying the crude product by adopting ultrafiltration membrane ultrafiltration and Sephadex G-15 gel column chromatography to obtain the peptide with good activity and high purity. The bioactive peptide can reduce lipid accumulation, ROS level, TNF-alpha content and IL-6 content in RAW264.7 foamed macrophages, and effectively improve lipid accumulation, oxidative stress and inflammatory state of the foamed macrophages, thereby inhibiting foaming of the macrophages.

The invention discloses application of pseudo-ginseng external vesicles in preparation of drugs for preventing or improving fatty liver diseases. Researches find that the pseudo-ginseng external vesicles can significantly reduce the levels of total cholesterol, triglyceride, asparaginic acid aminotransferase and alanine aminotransferase, down-regulate expression of fat synthesis related genes and inflammatory factors, improve lipid accumulation caused by fatty liver diseases, reduce body weight and liver-to-weight ratio, repair pathological damage of liver tissues and the like.

This invention belongs to the field of traditional Chinese medicine and discloses the application of total saponins extract of *Abrus precatorius* in the preparation of drugs for treating metabolic-associated fatty liver disease (MAFLD). Through experiments in high-fat diet-induced MAFLD mice, this invention demonstrates that total saponins of *Abrus precatorius* can protect the liver from a series of damages caused by excessive lipid accumulation. The potential mechanisms include regulating lipid metabolism through the PPAR and AMPK signaling pathways, and modulating the balance of gut microbiota. These findings provide a solid research foundation and empirical evidence for the potential application of total saponins of *Abrus precatorius* in the treatment of MAFLD.

The application discloses application of a benzofuro[3,2-c]quinolinone compound in preventing and treating metabolic dysfunction related steatohepatitis. The compound P82, i.e. 3,8-dihydroxybenzofuro[3,2-c]quinolin-6(5H)-one, is prepared through synthesis and purification of an intermediate, and can obviously improve liver steatosis, inflammatory infiltration and fibrosis in a metabolic dysfunction related steatohepatitis model induced by HFHC, thereby effectively delaying the progress of metabolic dysfunction related steatohepatitis. Meanwhile, the compound can improve lipid accumulation of liver cells induced by oleic acid and palmitic acid, and is expected to be developed into a new drug for preventing and treating metabolic dysfunction related steatohepatitis.

The invention provides a lipid nanoparticle. The lipid nanoparticle comprises a distearoyl phosphatidyl ethanolamine-polyethylene glycol derivative and a saturated fatty acid dimer as shown in a formula (I), wherein the mass ratio of the distearoyl phosphatidyl ethanolamine-polyethylene glycol derivative to the saturated fatty acid dimer is (10-30): (1-10). The saturated fatty acid dimer as shown in the formula (I) is delivered by adopting the distearoyl phosphatidyl ethanolamine-polyethylene glycol derivative, so that intracellular lipid accumulation and lipotoxicity effect can be induced, pyroptosis of tumor cells is promoted, systematic anti-tumor immune response is stimulated, and tumor growth is inhibited. More importantly, the lipid nanoparticles can enhance the sensitivity of liver cancer to PD-1 blocking treatment and significantly improve the combined treatment effect, no obvious toxic or side effect is observed, and the lipid nanoparticles show good clinical application prospects. (I).

The use of a berberine derivative NBD-125 in preparation of a drug for preventing and / or treating obesity is provided, belonging to the technical field of obesity treatment. Use of a berberine derivative NBD-125 in preparation of a drug for preventing and / or treating obesity is provided. The berberine derivative NBD-125 can prevent and / or treat obesity, with an effect significantly better than that of berberine. Moreover, the berberine derivative NBD-125 can inhibit weight gain, enhance metabolism and / or heat production, inhibit white adipose production, and inhibit differentiation of a preadipocyte into an adipocyte and / or lipid accumulation, where each inhibition index is better than that of the berberine.

The application relates to the field of biological medicine, and discloses an application of pachyman-derived extracellular vesicles and high-abundance miRNA thereof in relieving obesity. Cell experiments and animal experiments find that the pachyman-derived extracellular vesicles and high-abundance miRNA thereof can up-regulate the expression amount of key genes for brownification of white fat in 3T3-L1 adipocytes and mice in vivo, significantly improve glucose tolerance and insulin resistance of obese mice, and obviously relieve liver steatosis and lipid accumulation. Not only can the pachyman-derived extracellular vesicles and high-abundance miRNA thereof improve obesity from a phenotype, but also can regulate lipid metabolism, and have the value of being applied to preparation of medicines for preventing or relieving obesity and related metabolic complications.

This invention specifically discloses a novel chalcone compound, its preparation method, pharmaceutical composition, and applications. Experimental results show that this compound exhibits significant anti-inflammatory activity in a lipopolysaccharide-stimulated RAW 264.7 cell model, significantly superior to the positive control drug dexamethasone; and in a free fatty acid-treated HepG2 cell model, it exhibits significant inhibition of lipid accumulation, significantly superior to the positive control drug obeticholic acid. It can be used to develop drugs for the treatment of non-alcoholic fatty liver disease, including but not limited to simple fatty liver, non-alcoholic steatohepatitis, and related cirrhosis.

The object of the present invention is to provide a novel pharmaceutical composition for use in the treatment or prevention of lysosomal diseases, particularly Niemann-Pick disease. According to the present invention, there is provided a pharmaceutical composition for the treatment or prevention of a lysosomal disease, comprising as an active ingredient a modified γ-cyclodextrin in which a monovalent group derived from galacturonic acid is bonded to a sugar residue of the γ-cyclodextrin via an amide bond.

The present invention relates to a composition for regulating hepatic lipid metabolism, comprising Lactiplantibacillus plantarum OPT-A1 strain deposited under accession number KCTC 15555BP, a culture liquid thereof, a cultured product thereof, or a culture lysate thereof. The composition suppresses lipid accumulation and expression of genes related to lipogenesis in hepatocytes, and enhances expression of genes related to lipid oxidation. In addition, the composition inhibits accumulation of triglycerides in hepatocytes and reduces blood triglyceride levels, total cholesterol levels, and liver injury indices. Furthermore, the composition promotes rapid consumption of lipids in hepatocytes and somatic cells through enhancement of muscle mass, and thus can be advantageously used as a raw material for foods, pharmaceuticals, and the like related to alleviation and treatment of various metabolic diseases.

This invention discloses a method for preparing flavanone extracts through microbial co-fermentation and its application in lipid-lowering activity, belonging to the field of food nutrition and functional components. By co-fermenting orange peel raw materials with yeast and Monascus purpureus, the synergistic metabolic effects of different microorganisms are utilized to increase the content and reconstruct the composition of flavanones from orange peel. The bioactivity of the fermentation products was evaluated using a mouse 3T3-L1 preadipocyte differentiation model. The results showed that the flavanones from orange peel treated with co-fermentation had a significant inhibitory effect on lipid accumulation, and their lipid-lowering activity was significantly better than that of unfermented or single-strain fermentation products. The method of this invention is simple, reproducible, and suitable for large-scale production, and can be applied to the development of lipid-lowering functional health products or dietary supplements.

The invention provides application of a formula for treating hyperhomocysteinemia-derived atherosclerosis and relates to the technical field of application of formulas for treating hyperhomocysteinemia-derived atherosclerosis, and the formula has the unique advantages of multiple targets, multiple ways and low toxic and side effects, and is a medicine which is safe, effective and free of adverse reaction. The obvious effects are shown in the aspects of regulating Hcy metabolism, improving the vascular endothelial function, stabilizing the artery plaque and the like; at the same time, the Ersperm prescription can regulate lipid accumulation, inhibit inflammatory response, relieve oxidative stress injury and improve foaming of macrophages and VSMCs, thereby playing a role in relieving HHcy-derived atherosclerosis.

The human umbilical cord MSCs knocked down and expressing the METTL1 gene are constructed through lentivirus infection, secretion of NAMPT can be promoted, SIRT1 can be activated, accordingly, an SREBP1-mediated adipogenesis gene is inhibited, liver cell lipid accumulation is remarkably reduced in in-vitro and in-vivo MASLD models, and metabolic dysfunction related fatty liver diseases and insulin resistance are improved and treated.

The present application belongs to the technical field of pharmaceutical chemistry, and particularly relates to a kind of compound in the preparation of treating and / or preventing fatty liver disease and related diseases, more particularly to a kind of small molecule compound or its stereoisomer, its prodrug, its pharmaceutically acceptable salt or its pharmaceutically acceptable solvate in the preparation of treating and / or preventing fatty liver disease and related diseases.The compound of the present application can significantly inhibit lipid accumulation in hepatocytes, and no obvious toxic side effects are found, and the safety is high;can effectively inhibit HFD diet-induced weight gain, lipid accumulation, liver steatosis, and can reduce the content of triglyceride and total cholesterol in liver and serum, reduce the level of ALT and AST in plasma, has the effect of inhibiting liver damage and protecting liver function, and the effect is good.